The Rocky Mountain Multiple Sclerosis Center is a patient and family-centered nonprofit organization that provides a comprehensive and integrated wellness approach to MS and related diseases, life-changing support services, and cutting-edge research.
In this very interesting video there is a 20 minute explanation of Ocrelizumab including some comparison to existing disease modifying therapies.
If you wish to skip forward, at the 20 minute mark the question answer session begins which has some wonderful information on Ocrelizumab.
The FDA officially approved Ocrelizumab (brand name: Ocrevus) for use in multiple sclerosis treatment on March 28, 2017.
In this live Q&A, Dr. Enrique Alvarez answers some common questions on this new option for MS patients.